171 related articles for article (PubMed ID: 24946183)
1. Bisphosphonates and connexin 43: a critical review of evidence.
Sadr-Eshkevari P; Ashnagar S; Rashad A; Dietz M; Jackowski J; Abdulazim A; Prochnow N
Cell Commun Adhes; 2014 Oct; 21(5):241-7. PubMed ID: 24946183
[TBL] [Abstract][Full Text] [Related]
2. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs.
Plotkin LI; Manolagas SC; Bellido T
Bone; 2006 Sep; 39(3):443-52. PubMed ID: 16627025
[TBL] [Abstract][Full Text] [Related]
3. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability.
Bellido T; Plotkin LI
Bone; 2011 Jul; 49(1):50-5. PubMed ID: 20727997
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Russell RG; Xia Z; Dunford JE; Oppermann U; Kwaasi A; Hulley PA; Kavanagh KL; Triffitt JT; Lundy MW; Phipps RJ; Barnett BL; Coxon FP; Rogers MJ; Watts NB; Ebetino FH
Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
6. Zoledronate promotes bone formation by blocking osteocyte-osteoblast communication during bone defect healing.
Cui P; Liu H; Sun J; Amizuka N; Sun Q; Li M
Histol Histopathol; 2018 Jan; 33(1):89-99. PubMed ID: 28345127
[TBL] [Abstract][Full Text] [Related]
7. Bone-resorbing osteoclasts contain gap-junctional connexin-43.
Ilvesaro J; Väänänen K; Tuukkanen J
J Bone Miner Res; 2000 May; 15(5):919-26. PubMed ID: 10804022
[TBL] [Abstract][Full Text] [Related]
8. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo.
Plotkin LI; Lezcano V; Thostenson J; Weinstein RS; Manolagas SC; Bellido T
J Bone Miner Res; 2008 Nov; 23(11):1712-21. PubMed ID: 18597631
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
Jobke B; Milovanovic P; Amling M; Busse B
Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
[TBL] [Abstract][Full Text] [Related]
10. [Role of Gap junctions in bone tissue].
Wróbel E; Leszczyńska J; Przybylski J
Postepy Biochem; 2011; 57(4):411-7. PubMed ID: 22568173
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo studies using non-traditional bisphosphonates.
Plotkin LI; Buvinic S; Balanta-Melo J
Bone; 2020 May; 134():115301. PubMed ID: 32112989
[TBL] [Abstract][Full Text] [Related]
12. Gap junctional regulation of signal transduction in bone cells.
Buo AM; Stains JP
FEBS Lett; 2014 Apr; 588(8):1315-21. PubMed ID: 24486014
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of action of bisphosphonates.
Rodan GA
Annu Rev Pharmacol Toxicol; 1998; 38():375-88. PubMed ID: 9597160
[TBL] [Abstract][Full Text] [Related]
14. Enhanced osteoclastic resorption and responsiveness to mechanical load in gap junction deficient bone.
Zhang Y; Paul EM; Sathyendra V; Davison A; Sharkey N; Bronson S; Srinivasan S; Gross TS; Donahue HJ
PLoS One; 2011; 6(8):e23516. PubMed ID: 21897843
[TBL] [Abstract][Full Text] [Related]
15. Physiology of the aging bone and mechanisms of action of bisphosphonates.
Dominguez LJ; Di Bella G; Belvedere M; Barbagallo M
Biogerontology; 2011 Oct; 12(5):397-408. PubMed ID: 21695491
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.
Li B; Ling Chau JF; Wang X; Leong WF
J Cell Biochem; 2011 May; 112(5):1229-42. PubMed ID: 21465521
[TBL] [Abstract][Full Text] [Related]
17. The critical role of bisphosphonates to target bone cancer metastasis: an overview.
Singh T; Kaur V; Kumar M; Kaur P; Murthy RS; Rawal RK
J Drug Target; 2015 Jan; 23(1):1-15. PubMed ID: 25203856
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells.
Kaiser T; Teufel I; Geiger K; Vater Y; Aicher WK; Klein G; Fehm T
Breast Cancer Res Treat; 2013 Jul; 140(1):35-48. PubMed ID: 23807419
[TBL] [Abstract][Full Text] [Related]
19. ODDD-linked Cx43 mutants reduce endogenous Cx43 expression and function in osteoblasts and inhibit late stage differentiation.
McLachlan E; Plante I; Shao Q; Tong D; Kidder GM; Bernier SM; Laird DW
J Bone Miner Res; 2008 Jun; 23(6):928-38. PubMed ID: 18269311
[TBL] [Abstract][Full Text] [Related]
20. Regulation of osteoclastogenesis by gap junction communication.
Matemba SF; Lie A; Ransjö M
J Cell Biochem; 2006 Oct; 99(2):528-37. PubMed ID: 16639710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
